These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30895762)

  • 21. Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study.
    Izzo JL; Zappe DH; Jia Y; Hafeez K; Zhang J
    J Cardiovasc Pharmacol; 2017 Jun; 69(6):374-381. PubMed ID: 28338503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat.
    Rubattu S; Cotugno M; Forte M; Stanzione R; Bianchi F; Madonna M; Marchitti S; Volpe M
    J Hypertens; 2018 Sep; 36(9):1902-1914. PubMed ID: 29916993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.
    Wang L; Zhao JW; Liu B; Shi D; Zou Z; Shi XY
    Am J Cardiovasc Drugs; 2012 Oct; 12(5):335-44. PubMed ID: 22920046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.
    Chua SK; Lai WT; Chen LC; Hung HF
    J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34206864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.
    Ito S; Satoh M; Tamaki Y; Gotou H; Charney A; Okino N; Akahori M; Zhang J
    Hypertens Res; 2015 Apr; 38(4):269-75. PubMed ID: 25693859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
    Jackson AM; Jhund PS; Anand IS; Düngen HD; Lam CSP; Lefkowitz MP; Linssen G; Lund LH; Maggioni AP; Pfeffer MA; Rouleau JL; Saraiva JFK; Senni M; Vardeny O; Wijkman MO; Yilmaz MB; Saito Y; Zile MR; Solomon SD; McMurray JJV
    Eur Heart J; 2021 Sep; 42(36):3741-3752. PubMed ID: 34392331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy.
    Tuomilehto J; Tykarski A; Baumgart P; Reimund B; Le Breton S; Ferber P
    Blood Press Suppl; 2008 Jun; 1():15-23. PubMed ID: 18705531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
    Williams B; Cockcroft JR; Kario K; Zappe DH; Brunel PC; Wang Q; Guo W
    Hypertension; 2017 Mar; 69(3):411-420. PubMed ID: 28093466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study.
    Youn JC; Ihm SH; Bae JH; Park SM; Jeon DW; Jung BC; Park TH; Lee NH; Song JM; Yoon YW; Shin ES; Sung KC; Jung IH; Pyun WB; Joo SJ; Park WJ; Shin JH; Kang SM
    Clin Ther; 2014 Oct; 36(10):1412-21. PubMed ID: 25092393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study.
    Cheung DG; Aizenberg D; Gorbunov V; Hafeez K; Chen CW; Zhang J
    J Clin Hypertens (Greenwich); 2018 Jan; 20(1):150-158. PubMed ID: 29338113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic.
    Pogge EK; Davis LE
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):143-151. PubMed ID: 29455335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension.
    Wehland M; Simonsen U; Buus NH; Krüger M; Grimm D
    Expert Opin Pharmacother; 2020 Jul; 21(10):1133-1143. PubMed ID: 32133873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Twenty-Four-Hour Blood Pressure-Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double-Blind Multicenter Study.
    Kario K; Rakugi H; Yarimizu D; Morita Y; Eguchi S; Iekushi K
    J Am Heart Assoc; 2023 Apr; 12(8):e027612. PubMed ID: 37026551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
    Uijl E; 't Hart DC; Roksnoer LCW; Groningen MCC; van Veghel R; Garrelds IM; de Vries R; van der Vlag J; Zietse R; Nijenhuis T; Joles JA; Hoorn EJ; Danser AHJ
    J Hypertens; 2020 Apr; 38(4):755-764. PubMed ID: 31790054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.
    Assaad-Khalil SH; Najem R; Sison J; Kitchlew AR; Cho B; Ueng KC; DiTommaso S; Shete A
    Vasc Health Risk Manag; 2015; 11():71-8. PubMed ID: 25653536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials.
    Huang Y; Zhang Y; Ma L; Zhou H; Fang C; Chen C
    J Cardiovasc Pharmacol; 2021 Aug; 78(2):202-210. PubMed ID: 33929386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
    Dargad RR; Prajapati MR; Dargad RR; Parekh JD
    Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S102-S110. PubMed ID: 30122239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sacubitril/Valsartan as an Effective Hypertension Treatment Option in Those With Chronic Type B Aortic Dissection.
    Buhnerkempe MG; Bitner S; Flack JM
    Am J Hypertens; 2024 Jul; 37(8):543-545. PubMed ID: 38708518
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in peritoneal dialysis patients.
    He Y; Jin Y; Xue H; Liu R; Zhang M; Liao R; Chen M; Zhou X; He X; Qin M; Li K; Zou H; Gan Y; Wang Z; Zheng L; Zhong H; Fu P
    Nephrol Dial Transplant; 2023 Jul; 38(8):1880-1889. PubMed ID: 36787894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
    Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.